PharmTech Drug Digest 11.20
News|Articles|June 30, 2016

Califf Appoints Acting Director of Oncology Center of Excellence

Califf appointed Richard Pazdur as acting director of the Oncology Center of Excellence under the Cancer Moonshot Initiative.

On June 29, 2016 FDA Commissioner Robert Califf, MD, released a statement appointing Richard Pazdur as acting director of the Oncology Center of Excellence under Vice-President Joseph Biden’s Cancer Moonshot Initiative. Pazdur previously served as the director of Hematology and Oncology Products in the Center for Drug Evaluation and Research. According to Califf, Pazdur will play a critical role serving as the central point of engagement for oncology stakeholders, including patient-focused advocacy groups, professional associations, industry, academia, and sister agencies such as the National Institutes of Health.

The initiative, Califf says, calls on the agency to leverage the combined skills of regulatory scientists and reviewers with expertise in drugs, biologics, and devices to create the Oncology Center of Excellence (OCE). The OCE will expedite the development of novel combination products and support an integrated approach to treat cancer, Califf says. Biden’s Cancer Moonshot initiative is “aimed at speeding development of treatments by cutting bureaucracy and easing collaboration between scientists, industry, patients and government,” Reuters reports. The focus of the initiative is to double the rate of progress towards a cure for the disease in the next five years.

Source: FDA

 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.